Breaking News Instant updates and real-time market news.

SMMT

Summit Therapeutics

$1.50

(0.00%)

07:29
06/12/19
06/12
07:29
06/12/19
07:29

Summit Therapeutics no longer plans to intiate SMT-571 Phase 1 trial in 2H19

The company said, "SMT-571 is a new class antibiotic that is designed to treat infections caused by Neisseria gonorrhoeae. In February 2019, preclinical data was published in the Journal of Antimicrobial Chemotherapy that showed SMT-571 had consistently high potency across over 200 clinically relevant strains of N. gonorrhoeae, including numerous multi-drug resistant and extensively-drug resistant strains. IND-enabling studies are ongoing and expected to continue through the second half of the year. The Phase 1 clinical trial is no longer expected to initiate in H2 2019. Summit is evaluating the design of a clinical trial programme with the potential to shorten the overall clinical development timeline of SMT-571, subject to regulatory approvals. Further updates on the design and timelines for the start of the clinical programme to be provided when available. SMT-571 development is being supported by an award of up to $4.5M from CARB-X."

SMMT Summit Therapeutics
$1.50

(0.00%)

06/28/18
JMPS
06/28/18
DOWNGRADE
JMPS
Market Perform
Summit Therapeutics downgraded to Market Perform at JMP Securities
06/28/18
JANY
06/28/18
DOWNGRADE
JANY
Neutral
Summit Therapeutics downgraded to Neutral from Buy at Janney Montgomery Scott
06/28/18
RHCO
06/28/18
DOWNGRADE
Target $4
RHCO
Hold
Summit Therapeutics downgraded to Hold at SunTrust on failed phase 2 DMD study
As reported earlier, SunTrust analyst Edward Nash downgraded Summit Therapeutics to Hold from Buy and lowered his price target to $4 from $22. The analyst cites the company's failed phase 2 study on Duchenne muscular dystrophy treatment as its stock price plunged nearly 80% intraday, adding that Summit will now discontinue ezutromid development and focus on the antibiotic program for C difficile infection. Nash further notes that the company's new lead product candidate, Ridinilazole, is now expected to enter phase 3 trials in Q1 of FY19.
06/29/18
HCWC
06/29/18
NO CHANGE
Target $3
HCWC
Buy
Summit Therapeutics price target lowered to $3 from $20 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Summit Therapeutics to $3 after the company discontinued the development of ezutromid upon the full analysis of the 48-week data. Summit is now leveraged to its Phase 3 ready, differentiated, novel, gut flora sparing antibiotic for the treatment of Clostridium difficile, Chattopadhyay tells investors in a research note. Unfortunately, the Phase 3 program is not expected to commence until Q1 of 2019 and may not readout until 2021, the analyst adds. He believes, however, that the "damage to the stock is already done with the company trading at cash." Chattopadhyay sees "no value in moving to the sidelines" and keeps a Buy rating on Summit.

TODAY'S FREE FLY STORIES

SUNW

Sunworks

$0.55

-0.0424 (-7.19%)

08:12
06/27/19
06/27
08:12
06/27/19
08:12
Hot Stocks
Sunworks awarded follow-on order with Cibao Meat Products »

Sunworks announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$17.99

-0.015 (-0.08%)

08:11
06/27/19
06/27
08:11
06/27/19
08:11
Hot Stocks
SunGen Pharma partners with Athenex to launch Bivalirudin through PIV challenges »

SunGen Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

XERS

Xeris Pharmaceuticals

$10.64

-0.18 (-1.66%)

08:10
06/27/19
06/27
08:10
06/27/19
08:10
Hot Stocks
Xeris Pharmaceuticals doses first patient in ready-to-use glucagon Phase 2 trial »

Xeris Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Sep

  • 10

    Sep

CATB

Catabasis Pharmaceuticals

$7.67

0.17 (2.27%)

08:10
06/27/19
06/27
08:10
06/27/19
08:10
Hot Stocks
Catabasis Pharmaceuticals provides update on edasalonexent, qualitative research »

Catabasis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFOI

Energy Focus

$0.39

-0.0175 (-4.32%)

08:09
06/27/19
06/27
08:09
06/27/19
08:09
Hot Stocks
Energy Focus appoints Tod Nestor as president, CFO »

Energy Focus announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

08:07
06/27/19
06/27
08:07
06/27/19
08:07
Hot Stocks
Curaleaf Holdings makes two separate acquisitions in Arizona for $25.5M »

Curaleaf Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATOS

Atossa Genetics

$2.27

-0.035 (-1.52%)

08:07
06/27/19
06/27
08:07
06/27/19
08:07
Hot Stocks
Atossa says preliminary Phase 2 study of Endoxifen achieves primary endpoint »

Atossa Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$23.19

1 (4.51%)

08:06
06/27/19
06/27
08:06
06/27/19
08:06
Initiation
Adient initiated  »

Adient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANF

Abercrombie & Fitch

$15.85

0.49 (3.19%)

08:05
06/27/19
06/27
08:05
06/27/19
08:05
Hot Stocks
Green Growth Brands expands partnership with Abercrombie & Fitch »

Green Growth Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$39.43

-0.07 (-0.18%)

08:05
06/27/19
06/27
08:05
06/27/19
08:05
Hot Stocks
Zogenix announces FDA agreement to proceed with resubmission of FINTEPLA NDA »

Zogenix announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
06/27/19
06/27
08:05
06/27/19
08:05
General news
U.S. initial jobless claims preview: initial claims are expected to rise 5k to 221k »

U.S. initial jobless…

08:05
06/27/19
06/27
08:05
06/27/19
08:05
General news
U.S. Q1 GDP preview: w »

U.S. Q1 GDP preview:…

HTH

Hilltop Holdings

$20.05

0.26 (1.31%)

08:03
06/27/19
06/27
08:03
06/27/19
08:03
Hot Stocks
Hilltop Holdings signs sponsored research agreement with GWU »

Hoth Therapeutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Aug

HQY

HealthEquity

$62.16

-2.5 (-3.87%)

08:03
06/27/19
06/27
08:03
06/27/19
08:03
Conference/Events
HealthEquity to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ALRN

Aileron Therapeutics

$0.75

-0.0365 (-4.63%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Hot Stocks
Aileron Therapeutics announces FDA acceptance of IND for ALRN-6924 »

Aileron Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$375.05

5.68 (1.54%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Boeing analyst commentary  »

BofA continues to see 6-9…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 24

    Jul

CABO

Cable One

$1,111.46

-18.95 (-1.68%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Cable One analyst commentary  »

Cable One price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$85.74

0.32 (0.37%)

08:01
06/27/19
06/27
08:01
06/27/19
08:01
Recommendations
VF Corp. analyst commentary  »

VF Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

TSLA

Tesla

$219.22

-0.47 (-0.21%)

08:00
06/27/19
06/27
08:00
06/27/19
08:00
Options
Tesla put buyer realizes 36% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:57
06/27/19
06/27
07:57
06/27/19
07:57
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

BB

BlackBerry

$7.55

-0.74 (-8.93%)

07:56
06/27/19
06/27
07:56
06/27/19
07:56
Recommendations
BlackBerry analyst commentary  »

BlackBerry execution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SM

SM Energy

$12.56

0.63 (5.28%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Initiation
SM Energy initiated  »

SM Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

07:55
06/27/19
06/27
07:55
06/27/19
07:55
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

ITRI

Itron

$60.88

0.48 (0.79%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Conference/Events
Itron to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

XEC

Cimarex Energy

$57.17

1.64 (2.95%)

07:53
06/27/19
06/27
07:53
06/27/19
07:53
Initiation
Cimarex Energy initiated  »

Cimarex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.